Evidence map›Paper›PMID 36249063›Full record

ReviewFrontiers in oncology2022

Molecular testing for adolescent and young adult central nervous system tumors: A Canadian guideline.

Mary Jane Lim-Fat, Maria Macdonald, Sarah Lapointe, Seth Andrew Climans, Chantel Cacciotti, Manik Chahal, Sebastien Perreault, Derek S Tsang, Andrew Gao, Stephen Yip and 7 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Neuro-oncology advances
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Mary Jane Lim-FatDivision of Neurology, Department of Medicine, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada.
Maria MacdonaldDepartment of Oncology, London Health Sciences Centre, Schulich School of Medicine and Dentistry, University of Western Ontario, London, ON, Canada.
Sarah LapointeDivision of Neurology, Department of Medicine, Centre Hospitalier de l'Universite de Montreal, Montreal, QC, Canada.
Seth Andrew ClimansDepartment of Oncology, London Health Sciences Centre, Schulich School of Medicine and Dentistry, University of Western Ontario, London, ON, Canada.
Chantel CacciottiDepartment of Paediatrics, Division of Pediatric Hematology/Oncology, London Health Sciences Centre, London, ON, Canada.
Manik ChahalDepartment of Medical Oncology, BC Cancer Vancouver Centre, Vancouver, BC, Canada.
Sebastien PerreaultDepartment of Pediatrics, Division of Child Neurology, CHU Sainte-Justine, Montreal, QC, Canada.
Derek S TsangRadiation Medicine Program, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
Andrew GaoDepartment of Laboratory Medicine and Pathobiology, University Health Network, University of Toronto, Toronto, ON, Canada.
Stephen YipDepartment of Pathology & Laboratory Medicine, Faculty of Medicine, University of British Columbia, BC, Canada.
Julia KeithDepartment of Laboratory Medicine and Pathobiology, Sunnybrook Health Sciences Center, University of Toronto, Toronto, ON, Canada.
Julie BennettDivision of Haematology/Oncology, The Hospital for Sick Children, Toronto ON, Canada.
Vijay RamaswamyDivision of Haematology/Oncology, The Hospital for Sick Children, Toronto ON, Canada.
Jay DetskyDepartment of Radiation Oncology, Sunnybrook Health Sciences Center, University of Toronto, Toronto, ON, Canada.
Uri TaboriDivision of Haematology/Oncology, The Hospital for Sick Children, Toronto ON, Canada.
Sunit DasDivision of Neurosurgery, Department of Surgery, University of Toronto, Toronto, ON, Canada.
Cynthia HawkinsDepartment of Paediatric Laboratory Medicine, The Hospital for Sick Children, Toronto ON, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The 2021 World Health Organization (WHO) classification of CNS tumors incorporates molecular signatures with histology and has highlighted differences across pediatric vs adult-type CNS tumors. However, adolescent and young adults (AYA; aged 15-39), can suffer from tumors across this spectrum and is a recognized orphan population that requires multidisciplinary, specialized care, and often through a transition phase. To advocate for a uniform testing strategy in AYAs, pediatric and adult specialists from neuro-oncology, radiation oncology, neuropathology, and neurosurgery helped develop this review and testing framework through the Canadian AYA Neuro-Oncology Consortium. We propose a comprehensive approach to molecular testing in this unique population, based on the recent tumor classification and within the clinical framework of the provincial health care systems in Canada. Contributions to the field: While there are guidelines for testing in adult and pediatric CNS tumor populations, there is no consensus testing for AYA patients whose care occur in both pediatric and adult hospitals. Our review of the literature and guideline adopts a resource-effective and clinically-oriented approach to improve diagnosis and prognostication of brain tumors in the AYA population, as part of a nation-wide initiative to improve care for AYA patients.

Indexed as

AYACNS tumor classificationmolecular testingprecision oncologytargeted therapy

Identifiers

PMID36249063
PMCPMC9559579

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.